Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528996 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,080
- Enrollment target
NCT00528996 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,080 participants.
The verdict
NCT00528996, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,080 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives include comparing the effects on dyspnea and health status.
Interventions
- DRUG Placebo
- DRUG Tiotropium Bromide
- DRUG BEA 2180 BR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,080 participants |
| Start Date | 2007-09-06 |
| Est. Completion | 2009-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528996
The ClinicalTrials.gov registry entry for NCT00528996 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,080 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00528996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528996 about?
NCT00528996 is a clinical study titled "An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.". The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives include comparing the ef...
What is the current status of trial NCT00528996?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,080 participants. The study started on 2007-09-06. Estimated completion is 2009-05-05.
What interventions are being tested in trial NCT00528996?
The interventions under investigation include: Placebo (DRUG), Tiotropium Bromide (DRUG), BEA 2180 BR (DRUG).
Who is sponsoring clinical trial NCT00528996?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.